CapsoVision, Inc. (CV) is a Saratoga, California-based commercial-stage medical technology company that develops ingestible capsule endoscopy systems. Its flagship CapsoCam Plus uses multiple onboard cameras to image the small bowel, while CapsoCam Colon and CapsoColon 3D target the large intestine; the company pairs the hardware with a cloud software ecosystem for video review and AI-assisted reading. On Monday, the stock traded at $6.52, up $0.49 or 8.13%, from the prior close of $6.03. The move reversed part of Friday's 3.83% decline and pushed shares back above the level they held before the company's third-quarter report on November 12.
No verified news or fundamental catalyst found to account for the session's strength. No new filing, press release, analyst action, or company announcement accompanied the advance, and there was no broad-market or sector-wide event of comparable magnitude. The most defensible assessment is technical: after the November 12 report, shares slid to $5.86 on Friday and closed at $6.03, near the bottom of a three-week range, leaving the stock stretched to the downside. Monday's action is consistent with a relief rebound and short covering in an illiquid micro-cap, where a $350 million market capitalization on roughly 100,000 shares of average daily turnover produces a shallow order book. Individual one-minute prints during the afternoon ran in the hundreds of shares — the kind of thin flow that allows a modest imbalance of buyers to move the quote several percentage points. The move is also consistent with the stock's own behavior: its average absolute daily change over the past 60 sessions is 2.45%, and it has posted moves of 5% or more in seven of those sessions.
Although the report was released four sessions ago, its details remain the dominant fundamental reference point. Third-quarter revenue of roughly $3.6 million grew about 1% year over year, gross margin slipped to 49% on higher costs and a one-time charge, and operating expenses fell 8% to $9.1 million, partly on timing of a development agreement. The company ended September with about $21.8 million in cash against a burn rate near $2.4 million a month, and management has disclosed that additional capital raising will likely be required by early 2027 — a structural overhang that has kept a lid on rallies.
Against that, CapsoVision has accumulated genuine pipeline milestones: FDA clearance of AI Highlights for CapsoCam Plus, including pediatric use, completion of enrollment in the clinical study supporting its planned CapsoCam Colon submission, and an $18 million registered direct offering in September that brought in existing institutional holders at $5.69 a share. Management has guided that second-half revenue will exceed first-half revenue. None of these developments is new, but they are the reason buyers have repeatedly stepped in near $6.
There was no peer or sector rotation behind the move, and no macro release of comparable significance. The catalyst, to the extent one exists, was internal to the stock's own chart. Technically, Monday's advance lifted the shares back to roughly the 50-day average near $6.53, a level the stock lost on Friday. Immediate resistance sits in the $6.60-$7.05 band that capped the stock through late October and early November, while the November 13 low of $5.86 now marks near-term support. Volume patterns were unremarkable rather than confirming: the advance came through modest turnover rather than a decisive surge, which weakens the signal quality of the move. The stock remains roughly 58% below its 52-week high of $15.37, set in December 2025, and is still lower by double digits over the past month despite Monday's gain.
The scale runs from 0 — no meaningful news and a move that is entirely normal for the stock — to 100, meaning transformative news combined with an extreme, rare price move. CapsoVision scores 32 out of 100. The verified news component is weak: no fresh disclosure or analyst action drove Monday's session, and the most recent material items, the third-quarter report and prior FDA milestones, had already been digested. The price component is stronger. Monday's 8.13% gain was about 3.3 times the stock's 2.45% average absolute daily move, and only one of the last 60 sessions produced a larger absolute change — the 9.5% decline on November 5. A genuine but low-materiality news backdrop combined with a moderately unusual move yields the mid-30s score.
The next hard catalyst is the planned CapsoCam Colon submission to the FDA, which management has targeted before the end of 2026. Commercial traction for AI Highlights and the pace of U.S. capsule volume will be the key read on whether the growth story is holding. Financing is the central risk: with cash sufficient for roughly three quarters at the current burn, any capital raise — through the at-the-money program or a new offering — could pressure the share price and add dilution. Fourth-quarter results are expected in late March 2027, with two analysts currently carrying a consensus Strong Buy rating. Sector sentiment toward small-cap medical devices and the broader appetite for unprofitable medtech will continue to shape the trading range.
Tickeron operates hundreds of AI trading bots that cover thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. The bots differ widely by strategy, timeframe, performance metrics, and traded symbols, so the page offers a useful starting point for comparing approaches side by side. Reviewing the current leaders can help you judge which automated strategies are adapting best to present volatility. Explore the featured robots and see how they are positioned today.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +3.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where CV advanced for three days, in 63 of 73 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
CV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 31 of 34 cases where CV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CV as a result. In 23 of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for CV turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 8 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
CV moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CV crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 3 of 4 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CV's P/B Ratio (25.542) is slightly higher than the industry average of (4.142). P/E Ratio (-5.672) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (21.598) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. CV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices